Form 4: Mirum Pharmaceuticals Director Laurent Fischer Reports Stock Option and Deferred Stock Unit Acquisition

Director Laurent Fischer reports acquisition of stock options and deferred stock units in Mirum Pharmaceuticals.

Summary

• On June 5, 2024, Laurent Fischer, a director of Mirum Pharmaceuticals, acquired 8,779 stock options with an exercise price of $26.30.
• These options vest on the first anniversary of the grant date but will be fully vested by the date of the Issuer's 2025 annual stockholder meeting.
• Fischer also acquired 5,703 deferred stock units, each representing a contingent right to receive one share of Mirum Pharmaceuticals' common stock.
• These deferred stock units also vest on the first anniversary of the grant date, with full vesting by the date of the Issuer's 2025 annual stockholder meeting.
• Vested deferred stock units will be paid out in common stock upon a change in control of the Issuer or within 60 days following separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and deferred stock units by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options and deferred stock units by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule of the stock options and deferred stock units is tied to the first anniversary of the grant date and the Issuer's 2025 annual stockholder meeting, suggesting a focus on long-term performance and alignment with shareholder interests.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of stock options and deferred stock units by a director could positively influence shareholder sentiment.

Key Dates